Objective: This prospective study was designed to determine whether variation in angiogenic (placental growth factor [PlGF]) and/or anti-angiogenic (soluble fms-like tyrosine kinase [sFlt-1]) factors contribute to the protective effect of highland ancestry (Andean) from altitude-associated reductions in fetal growth. Study design: Plasma sFlt-1 and PlGF levels, uterine artery (UA) blood flow, and fetal biometry were determined in low-altitude (400 m; Andean n = 27, European n = 28) and high-altitude (3600 m; Andean n = 51, European n = 44) residents during pregnancy (20 and 36 weeks) and 4 months postpartum. Results: High-altitude decreased sFlt-1 levels in both groups, Andeans had lower sFlt-1, comparable PlGF, lower sFlt-1/PlGF ratios, and higher UA blood flow throughout pregnancy relative to Europeans. Altitude decreased birth weight in Europeans but not Andeans. In high-altitude Europeans sFlt-1/PlGF and sFlt-1 levels were negatively associated with UA diameter and birth weight, respectively. Conclusions: Lower sFlt-1 and sFlt-1/PLGF ratio may contribute to or result from variations in maternal vascular adaptation to pregnancy between Andean and Europeans at high altitude. Subsequently, these effects could potentially influence ancestry-associated differences in birth weight.
Zygmunt M., Herr F., Munstedt K., Lang U., Liang ODAngiogenesis and vasculogenesis in pregnancy. Eur J Obstet Gynecol Reprod Biol. 2003;110(suppl 1):S10-S18.
2.
Cross JC, Hemberger M., Lu Y., et al. Trophoblast functions, angiogenesis and remodeling of the maternal vasculature in the placenta. Mol Cell Endocrinol. 2002;187(1-2):207-212.
3.
Osol G., Celia G., Gokina N., et al. Placental growth factor is a potent vasodilator of rat and human resistance arteries. Am J Physiol Heart Circ Physiol. 2008;294(3):H1381-H1387.
4.
Charnock-Jones DS, Kaufmann P., Mayhew TMAspects of human fetoplacental vasculogenesis and angiogenesis. I. Molecular regulation. Placenta. 2004;25(2-3):103-113.
5.
Zamudio S., Palmer SK, Droma T., Stamm E., Coffin C., Moore LGEffect of altitude on uterine artery blood flow during normal pregnancy. J Appl Physiol. 1995;79(1):7-14.
6.
Julian CG, Galan HL, Wilson MJ, et al. Lower uterine artery blood flow and higher endothelin relative to nitric oxide metabolite levels are associated with reductions in birth weight at high altitude. Am J Physiol Regul Integr Comp Physiol.2008;295(3): R906-R915.
7.
Krampl E., Lees C., Bland JM, Espinoza Dorado J., Moscoso G., Campbell S.Fetal biometry at 4300 m compared to sea level in Peru. Ultrasound Obstet Gynecol. 2000;16(1):9-18.
8.
Keyes LE, Armaza JF, Niermeyer S., Vargas E., Young DA, Moore LGIntrauterine growth restriction, preeclampsia, and intrauterine mortality at high altitude in Bolivia. Pediatr Res. 2003;54(1):20-25.
9.
Julian CG, Vargas E., Armaza JF, Wilson MJ, Niermeyer S., Moore LGHigh-altitude ancestry protects against hypoxia-associated reductions in fetal growth. Arch Dis Child Fetal Neonatal Ed. 2007;92(5):F372-F377.
10.
Palmer SK, Moore LG, Young D., Cregger B., Berman JC, Zamudio S.Altered blood pressure course during normal pregnancy and increased preeclampsia at high altitude (3100 m) in Colorado. Am J Obstet Gynecol . 1999;180(5):1161-1168.
11.
Moore LGFetal growth restriction and maternal oxygen transport during high altitude pregnancy. High Alt Med Biol. 2003;4(2): 141-156.
12.
Moore LG, Shriver M., Bemis L., et al. Maternal adaptation to high-altitude pregnancy: an experiment of nature-a review. Placenta. 2004;25(suppl A):S60-S71.
13.
Wilson MJ, Lopez M., Vargas M., et al. Greater uterine artery blood flow during pregnancy in multigenerational (Andean) than shorter-term (European) high-altitude residents. Am J Physiol Regul Integr Comp Physiol. 2007;293(3): R1313-R1324.
14.
Zamudio S., Postigo L., Illsley NP, et al. Maternal oxygen delivery is not related to altitude- and ancestry-associated differences in human fetal growth. J Physiol. 2007;582(pt 2):883-895.
15.
Julian CG, Wilson MJ, Lopez M., et al. Augmented uterine artery blood flow and oxygen delivery protect Andeans from altitude-associated reductions in fetal growth. Am J Physiol Regul Integr Comp Physiol.2009;296(5):R1564-1575.
16.
Szukiewicz D. , Szewczyk G., Watroba M., Kurowska E., Maslinski S.Isolated placental vessel response to vascular endothelial growth factor and placenta growth factor in normal and growth-restricted pregnancy. Gynecol Obstet Invest. 2005;59(2):102-107.
17.
Cooper B.Mechanism of vasodilation by placental growth factor (PIGF) in the uterine circulation. J Soc Gynecol Invest. 2005;12(2).
18.
Bulla R., Bossi F., Radillo O., de Seta F., Tedesco F.Placental trophoblast and endothelial cells as target of maternal immune response . Autoimmunity. 2003;36(1):11-18.
19.
Teran E., Escudero C., Moya W., Flores M., Vallance P., Lopez-Jaramillo P. Elevated C-reactive protein and pro-inflammatory cytokines in Andean women with pre-eclampsia. Int J Gynaecol Obstet . 2001;75(3):243-249.
20.
Nagamatsu T. , Fujii T., Kusumi M., et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia . Endocrinology. 2004;145(11):4838-4845.
21.
Levine RJ, Maynard SE, Qian C., et al. Circulating angiogenic factors and the risk of preeclampsia . N Engl J Med. 2004;350(7): 672-683.
22.
Romero R., Nien JK, Espinoza J., et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med. 2008;21(1):9-23.
23.
Smith GC, Crossley JA, Aitken DA, et al. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet Gynecol. 2007;109(6):1316-1324.
24.
Ahmed A., Dunk C., Ahmad S., Khaliq A.Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen-a review. Placenta. 2000;21(suppl A):S16-S24.
25.
Lash GE, Taylor CM, Trew AJ, et al. Vascular endothelial growth factor and placental growth factor release in cultured trophoblast cells under different oxygen tensions. Growth Factors. 2002;20(4):189-196.
26.
Shriver MD, Kennedy GC, Parra EJ, et al. The genomic distribution of population substructure in four populations using 8,525 autosomal SNPs. Hum Genomics. 2004;1(4):274-286.
27.
Bahtiyar MO , Buhimschi C., Ravishankar V., et al. Contrasting effects of chronic hypoxia and nitric oxide synthase inhibition on circulating angiogenic factors in a rat model of growth restriction. Am J Obstet Gynecol.2007;196(1):72.e1-72.e6.
28.
Krauss T., Pauer HU, Augustin HGProspective analysis of placenta growth factor (PlGF) concentrations in the plasma of women with normal pregnancy and pregnancies complicated by preeclampsia . Hypertens Pregnancy. 2004;23(1):101-111.
29.
Zamudio S.The placenta at high altitude. High Alt Med Biol. 2003;4(2):171-191.
30.
Schlembach D., Wallner W., Sengenberger R., et al. Angiogenic growth factor levels in maternal and fetal blood: correlation with Doppler ultrasound parameters in pregnancies complicated by pre-eclampsia and intrauterine growth restriction . Ultrasound Obstet Gynecol. 2007;29(4):407-413.
31.
Savvidou MD , Yu CK, Harland LC, Hingorani AD, Nicolaides KHMaternal serum concentration of soluble fms-like tyrosine kinase 1 and vascular endothelial growth factor in women with abnormal uterine artery Doppler and in those with fetal growth restriction. Am J Obstet Gynecol. 2006;195(6):1668-1673.
32.
Chaiworapongsa T., Espinoza J., Gotsch F., et al. The maternal plasma soluble vascular endothelial growth factor receptor-1 concentration is elevated in SGA and the magnitude of the increase relates to Doppler abnormalities in the maternal and fetal circulation. J Matern Fetal Neonatal Med. 2008;21(1): 25-40.
33.
Stepan H., Unversucht A., Wessel N., Faber R.Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension. 2007;49(4): 818-824.
34.
Shibuya M.Vascular endothelial growth factor receptor-1 (VEGFR-1/Flt-1): a dual regulator for angiogenesis. Angiogenesis. 2006;9(4):225-230; discussion 231.
35.
Cao Y.Positive and negative modulation of angiogenesis by VEGFR1 ligands. Sci Signal. 2009;2(59):re1.
36.
Nevo O., Soleymanlou N., Wu Y., et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol.2006;291(4):R1085-R1093.
37.
Li H., Gu B., Zhang Y., Lewis DF, Wang Y.Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta. 2005;26(2-3):210-217.
38.
Rajakumar A. , Michael HM, Rajakumar PA, et al. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta. 2005;26(7):563-573.
39.
Facco M., Zilli C., Siviero M., et al. Modulation of immune response by the acute and chronic exposure to high altitude. Med Sci Sports Exerc. 2005 ;37(5):768-774.
40.
Rana S., Karumanchi SA, Levine RJ, et al. Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension. 2007;50(1):137-142.
41.
Ahmad S., Ahmed A.Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res. 2004 ;95(9):884-891.
42.
Wallner W., Sengenberger R., Strick R., et al. Angiogenic growth factors in maternal and fetal serum in pregnancies complicated by intrauterine growth restriction. Clin Sci (Lond). 2007;112(1): 51-57.
43.
Levine RJ, Lam C., Qian C., et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med. 2006;355(10):992-1005.
44.
Greer IA, Lyall F., Perera T., Boswell F., Macara LMIncreased concentrations of cytokines interleukin-6 and interleukin-1 receptor antagonist in plasma of women with preeclampsia: a mechanism for endothelial dysfunction? Obstet Gynecol. 1994;84(6):937-940.
45.
Laskowska M. , Leszczynska-Gorzelak B., Laskowska K., Oleszczuk J.Evaluation of maternal and umbilical serum TNFalpha levels in preeclamptic pregnancies in the intrauterine normal and growth-restricted fetus. J Matern Fetal Neonatal Med. 2006;19(6):347-351.
46.
Bartha JL, Romero-Carmona R., Comino-Delgado R.Inflammatory cytokines in intrauterine growth retardation. Acta Obstet Gynecol Scand. 2003;82(12):1099-1102.
